A new asthma therapy which is being developed by AstraZeneca in collaboration with Avillion has shown positive results from a phase 3 trial. The Pharma Times reports that the treatment, known as PT027, is a fixed-dose combination of albuterol and budesonide.

The novel therapy in inhaled, to treat the symptoms of patients suffering from severe to moderate levels of asthma. The short-acting drug showed a statistically significant reduction in an episode of severe asthma, in comparison with a control treatment during clinical trials.

Allison Jeynes, CEO of Avillion, said: “Building on the positive high-level results for MANDALA and DENALI announced in September last year, it’s fantastic to receive further confirmation of PT027’s potential in reducing the significant burden that asthma presents to millions of people worldwide.”

She added: “With the completion of this pivotal programme, Avillion maintains its 100% trial success rate across multiple therapy areas.”

“This is an impressive achievement and demonstrates the power of our clinical co-development model and the quality of our international team in advancing vital drugs in partnership with pharma and biotech companies.”

Asthma is a common condition which affects the lungs, and about 5.4 million people in the UK have a diagnosis, according to the charity Asthma & Lung UK. It often manifests itself in childhood, but adults can sometimes develop it during later life. Common symptoms include coughing, wheezing, and breathlessness.

To be managed successfully, it needs to be treated every day, although the symptoms may come and go. The condition often goes hand in hand with allergies and eczema, and it can be triggered by dust mites, spores from pets, pollen, pollution, hay fever, smoking, hormonal changes, or stress.

Most people can manage their symptoms through consistent use of a preventer inhaler and a reliever inhaler. However, asthma attacks happen when symptoms intensify suddenly, and sadly four people in the UK die from an asthma attack every day.

Patients are advised to learn to spot the early symptoms of an asthma attack. These include feeling more breathless than usual, coughing more, a tight chest, disrupted sleep, wheezing more, and increased use of the reliever inhaler. All these are a sign of worsening inflammation, and medical advice should be sought immediately.

The medical professional may recommend increasing the dose of your preventer inhaler, or adjusting your technique. They may also ask about nay new triggers you may have encountered, including difficult or stressful situations.

Strong emotions, even for a positive reason, are a known trigger for asthma attacks. Children often have an attack after a fit of laughing or crying, for example, and parents are often careful around events where emotions tend to run high, such as Christmas or birthdays.

Adults experience strong emotions too of course, and it is not always possible to avoid them. However, taking preventer medication on a regular basis, and using it properly, can help. Patients are also advised to avoid smoking, take regular exercise, and maintain a healthy weight.

If you are looking for global pharmaceuticals wholesale, please visit our website today.